Olema Pharmaceuticals Bolsa (NASDAQ: OLMA)

Olema Pharmaceuticals (NASDAQ:OLMA) Bolsa

OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ABTS

DEVS

GIBO

IXHL

MTUS

NVVE

Next Technology Holding Inc. - Ordinary Shares

NXTT

OLMA

RSLS

RYDE

SHPH

SISI

SYTA

TAOP

Las acciones de Sable Offshore suben un 12,6 % en la preapertura tras publicar resultados del primer trimestre.

Las acciones de Sable Offshore (SOC) suben un 13%; Aquí están 20 acciones que se mueven en premercado

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Long Ideas

MODV

Descubre las principales acciones sobrevendidas del sector sanitario con RSI bajo 30, incluyendo SLN, MODV y OLMA.

Las acciones más sobrevendidas del sector sanitario con RSI bajo 30

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals inc

WIIM

T1 Energy shares are trading higher after the company selected a contractor for preconstruction services and site preparations its $850 million planned 5 GW solar cell plant.

VSCO

Victoria's Secret shares are trading higher after WSJ reported Barington Capital holds over a 1% stake and plans to push for a board overhaul and renewed focus on core products

SAGE

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

US Steel shares are trading higher after President Trump approved Nippon Steel's partnership with the company.

SATS

EchoStar shares are trading higher after President Trump reportedly urged Ergen and Carr to cut a deal on the company's spectrum

SRPT

Sarepta shares are trading lower after the company suspended ELEVIDYS shipments and paused the ENVISION trial following a second fatal liver failure in non-ambulatory Duchenne patients.

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Buy and maintains $35 price target.

Price Target

Analyst Ratings

IMAX

Rosenblatt Maintains Buy on Imax, Maintains $35 Price Target

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lumen.com&amp;esheet=54276416&amp;newsitemid=20250615330222&amp;lan=en-US&amp;anchor=Lumen+Technologies%2C+Inc.&amp;index=1&amp;md5=16be0874577993a0c90075ad4b2b6765">Lumen Technologies, Inc.</a> ("Lumen", "us," "we" or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. ("Level 3 Financing"), plans to offer $1.0 billion aggregate principal amount of First Lien Notes due 2033 (the "First Lien Notes").
Level 3 Financing intends to use the net proceeds from the offering, together with cash on hand, to redeem all $924.522 million aggregate principal amount of Level 3 Financing's first lien 10.500% Senior Secured Notes due 2030 (the "2030 Notes"), including payment of redemption premium, and to pay related fees and expenses.
The First Lien Notes will not be registered under the Securities Act of 1933 (the "Securities Act") or any state securities laws in the United States and may not be offered or sold in the United States absent registration or an exemption from the applicable registration requirements. Accordingly, the First Lien Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A promulgated under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S promulgated under the Securities Act. The First Lien Notes will not have registration rights.

Offerings

LUMN

Lumen Plans $1B Bond Offering to Pay Off High-Interest Debt and Cut Costs by 2030

Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) will release its fourth-quarter financial results after the closing <a href="https://www.benzinga.com/quote/XAIR/earnings">bell on Tuesday, June 17</a>.
Analysts expect the Garden City, New York-based company to report quarterly revenue of $1.39 million, compared to $470,000 a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 21, Beyond Air announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.
Beyond Air shares fell 3% to close at $0.1779 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/xair/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/GBX/analyst-ratings">have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral on June 25, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Truist Securities analyst Gregory Fraser maintained a Buy rating and lowered the price target from $10 to $8 on April 30, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying XAIR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/XAIR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-1024x611.png" alt="" class="wp-image-950593" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Earnings

XAIR

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $5 price target.

Rosenblatt Maintains Buy on Canaan, Maintains $5 Price Target

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) on Monday announced at <a href="https://www.benzinga.com/pressreleases/25/06/b45943027/adobe-llm-optimizer-empowers-businesses-to-drive-brand-visibility-as-consumers-embrace-ai-powered-">the Cannes Lions International Festival of Creativity</a> the launch of Adobe LLM Optimizer, a new enterprise application designed to help businesses enhance brand relevance and visibility as consumers increasingly adopt generative AI-powered interfaces for brand engagement and discovery.
The core function of the LLM Optimizer is to equip businesses with the tools to monitor, analyze, and enhance their presence within Large Language Model (LLM) powered environments. 
This will allow companies to track traffic originating from AI-driven sources and compare their brand&#8217;s visibility against competitors. 
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932918/adobe-stock-undervalued-analyst-says-as-it-breaks-from-cautious-tech-pack-lifts-guidance" target="_blank" rel="noreferrer noopener">Adobe Stock Undervalued, Says Analyst As It Breaks From Cautious Tech Pack, Lifts Guidance</a>
The system will then provide actionable recommendations to improve how a brand&#8217;s content is discovered and presented in AI-generated responses.
Highlighting the urgency and relevance of this new tool, Adobe shared insights from its own analytics, revealing a staggering 3,500% increase in traffic to U.S. retail sites from generative AI sources between July 2024 and May 2025. 
Adobe&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45943028/lumen-technologies-scales-b2b-personalization-with-generative-ai-innovations-in-adobe-genstudio" rel="noreferrer noopener">also announced that</a> Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) is embracing&nbsp;Adobe GenStudio&nbsp;to activate generative AI across their organization, shortening the time it takes to deliver personalized business-to-business (B2B) marketing campaigns.
The collaboration has yielded impressive results, most notably reducing the time required to launch a B2B marketing campaign from 25 days down to just 9 days, the company said in a press release. 
This increased efficiency is driven by Adobe GenStudio for Performance Marketing, which uses generative AI to produce on-brand content for various digital channels, including social media and email.
Lumen is utilizing Adobe Firefly and Custom Models to quickly generate brand-compliant campaign imagery tailored to different audiences and industries. This has reduced the time to create ad variations by 65%.
The tools enable Lumen to scale the production of highly tailored content for B2B decision-makers across the 10 industries it serves, which is crucial for long and complex sales cycles.
By integrating solutions like Adobe Workfront for work management and Adobe Express for content creation, Lumen has simplified collaboration between its creative and marketing teams, ensuring a seamless approval process and brand consistency.
Price Action:&nbsp;ADBE stock is trading higher by 0.08% to $392.00 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45928757/amd-serious-ai-contender-with-sights-on-over-500-billion-tam-billions-in-revenue-analyst" target="_blank" rel="noreferrer noopener">AMD &#8216;Serious AI Contender&#8217; With Sights On Over $500 Billion TAM, Billions In Revenue: Analyst</a></li>
</ul>
Photo by Charles-McClintock Wilson via Shutterstock

Tech

ADBE

Adobe To Help Brands Win The AI Search Game With New LLM Optimizer

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $20 price target.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Maintains $20 Price Target

Updated Phase 2 data evaluating ZYNLONTA&#xAE; as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%
CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment
ZYNLONTA was generally well tolerated and safety was consistent with known profile
LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ --&nbsp;ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data&nbsp;from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA&#xAE; to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18,&nbsp;at 8:30 a.m. CEST. The single-arm, open-label, study is led by Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

ADCT

ADC Therapeutics To Present Updated Data From Phase 2 Multicenter IIT Of ZYNLONTA To Treat r/r MZL, At International Conference on Malignant Lymphoma

Rosenblatt analyst Chris Brendler maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $300 price target.

COIN

Rosenblatt Maintains Buy on Coinbase Global, Maintains $300 Price Target

RYVYL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) ("RYVYL" or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, has submitted a registration statement on Form S-1 with the Securities and Exchange Commission. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Additionally, management is executing strategic actions and enhancing its business plan:
<ul>
<li>RYVYL is
<ul>
<li>Focusing on growing its North America revenues, including pursuing a legacy vertical market, which at its peak, in the fourth quarter of 2023, delivered revenue of $12 million;</li>
<li>Expanding its blockchain applications and crypto capabilities; and</li>
<li>Rightsizing the company as detailed below.</li>
</ul>
</li>
<li>The company has entered into a letter of intent (LOI) to acquire an entity with technology and digital assets that are complementary.</li>
<li>RYVYL has closed the sale of RYVYL EU, its wholly owned European subsidiary, and the transaction is complete. The company has withdrawn its previous guidance for 2025.</li>
</ul>
Cost Savings Initiatives and Organizational Realignment
In addition, on May 31, 2025, RYVYL realigned its corporate and North America operations and implemented a reduction in force of 18 employees, representing approximately 40% of its North America workforce. Savings from this action along with other reductions are expected to result in savings of approximately $780,000 per quarter. Plans to reduce outside engineering contractors during the second quarter of 2025 are expected to result in savings of approximately $265,000 per quarter. The Company expects the full impact of these savings to begin in the third quarter of 2025.
Additional Terms
The offering is expected to commence after the SEC completes its review process, subject to market and other conditions. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
There are no assurances that the Company will close the acquisition or that the Enhanced Business Plan would result in a significant benefit to the Company. In addition, the Acquisition and Enhanced Business Plan would be dependent upon the Company raising a minimum of $100 million, which would require shareholder approval of (i) the Acquisition, (ii) a potential increase in the authorized amount of common stock of the Company, and (iii) a potential reverse split of the common stock of the Company.

IPOs

RVYL

RYVYL Files for Stock Offering, Plans Cost Cuts and Crypto Expansion to Refocus US Business

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") is pleased to announce that is has finalized a number of drill targets at the Sakami gold project located in the Eeyou Istchee Territory in the James Bay region of Northern Quebec (Figure 1). The first phase drilling campaign will commence in late June 2025 and will be comprised of approximately 3,000 – 5,000 metres (m), with three priorities;
<ol>
<li>Discovery along a 23-kilometre (km) long gold-bearing structural corridor at the Juliette target;</li>
<li>Confirm historical mineralized intercepts at the La Pointe and La Pointe Extension targets;</li>
<li>Stepout drilling along strike and down plunge of a high-grade corridor identified at La Pointe Extension.</li>
</ol>

FURY

Fury Gold Mines Finalizes Number Of Drill Targets At Sakami Gold Project Located In Eeyou Istchee Territory In James Bay Region Of Northern Quebec

AMWD

American Woodmark CFO Paul Joachimczyk Resigns, CEO Scott Culbreth Named Interim Financial Officer

<a href="https://www.globenewswire.com/Tracker?data=rv7o-H8l-jTHoqhdWSfawILWPvFTQwhluDyjODnmujzbKOlDii3m1SfQwRofUtfEQIuvCNgbSbw9HdyRZfS4gA==">USA Rare Earth</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company) today announced it has signed a memorandum of understanding (MOU) with <a href="https://www.globenewswire.com/Tracker?data=BJyFqA3nAW4K9A56mCaK375RJQBr0MTWob_6mw-Dq2Q-GpnyRKzLGRYBdWxs0jE67QBXgZuFMgjslooskSXT5pQ1mbbNj7NjpL-sQzOLVAE=">Moog Electric Motion Solutions</a> (Moog) for delivery of the Company's neo magnets, of which USAR plans to begin production in early 2026. Moog Electric Motion Solutions provides precision motion and fluid control systems and will begin prototyping USAR's neo magnets for use in Moog's high-performance coolant distribution pumps used in data centers around the world.
The MOU is the latest in a series of agreements with potential customers announced by the Company following the March 31, 2025, commissioning of its Innovations Lab in Stillwater, Oklahoma. USAR's Innovations Lab mimics the production capabilities of the USAR's commercial manufacturing facility once commissioned in 2026. This capability now allows the Company to begin prototyping magnets and move through the qualification processes of potential customers, like Moog, as it seeks to scale up to its initial capacity next year.
"We continue our mission to bring the rare earth supply chain back to the broader technology market here in the U.S.," said Joshua Ballard, CEO of USA Rare Earth. "We are excited to support Moog in bringing their magnets back home to America, a leader in so many critical industries in need of neo magnetic applications. We look forward to building a lasting partnership for many years to come."
As part of the agreement, USA Rare Earth will design and test permanent Neodymium magnets for use in Moog's CoreMotion&#x2122; technology, which is driving energy efficiency in data centers deployed globally.

USAR

USA Rare Earth Partners With Moog to Bring Magnet Production Back to America for Global Data Centers

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161-
-This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160-
NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,&nbsp;today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan.
Depending on the individual's deductible and out-of-pocket costs, these claims may not result in an immediate PoNS Device sale.

HSDT

Helius Medical Technologies Announces Additional Authorized Claim For Payment For PoNS Device From CignaHealth

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
—Patients report improved quality of life and daily functioning with ORLADEYO—

BCRX

BioCryst Reports Sustained Benefits Of Berotralstat in Children, Adolescents, And Adults With Hereditary Angioedema

Press Releases

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Health Care

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

Comments

Olema Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL